Inovio said the FDA granted a speedy approval for Voceryq, its DNA-based immunotherapy for a rare tumor type, giving the company a new marketed asset in a niche indication. The company positioned Voceryq to compete with Precigen’s therapy for recurrent respiratory papillomatosis, which was the first FDA-approved drug for the condition. Both products carry the same $460,000 list price, but Inovio executives pointed to additional competitive advantages for its approach. For investors, the approval reinforces continued regulatory openness to non-traditional immunotherapy platforms, particularly in settings where treatment options are limited and endpoints can be met with smaller clinical datasets.